Trials / Completed
CompletedNCT00553865
Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets
A 8-Week, Randomized, Double-blind, Parallel Designed, Phase II Multi-center Clinical Trial to Evaluate the Antihypertensive Efficacy and the Safety of OJP-2028 Tablets in Patients With the Uncomplicated Essential Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Jeil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
Detailed description
Evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OJP-2028 | Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-10-01
- Completion
- 2008-11-01
- First posted
- 2007-11-06
- Last updated
- 2016-06-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00553865. Inclusion in this directory is not an endorsement.